Recent studies point to promising new therapeutic options that can be applied in the presence of certain gene fusion events (such as NTRK gene fusions). Diagnostic labs can use RNA sequencing to detect such fusion events. The source material (e.g. tumor tissue) has to be prepared for sequencing using custom-made assays or using commercial assays such as Archer® FusionPlex®.
Given that recently a new module for detecting fusion events was introduced to the Seamless NGS software platform, the developers were interested in how sensitive their approach is on existing data. Find out how the software platform performed: https://www.ecseq.com/blog/2020/Impr...ionPlex-Panels
Given that recently a new module for detecting fusion events was introduced to the Seamless NGS software platform, the developers were interested in how sensitive their approach is on existing data. Find out how the software platform performed: https://www.ecseq.com/blog/2020/Impr...ionPlex-Panels
